Coya Q2 2026 net loss $6.6M; cash $43.2M funds ALS trial into 2H27

Coya Therapeutics, Inc.

Net loss $6.6M for Q2 2026 vs $6.1M in Q2 2025; R&D up $1.3M to $5.0M on COYA 302 ALS trial costs.
Cash and equivalents $43.2M at June 30, 2026, expected to fund operations past Phase 2 ALSTARS readout into 2H 2027.
FDA granted Fast Track Designation for COYA 302 in ALS; first cohort advanced into 24-week blinded active treatment extension.
Collaboration revenue flat at $0.2M under DRL agreement; G&A down $0.6M to $2.3M.
On track to complete ALSTARS enrollment in 2H 2026 and report topline data in Q1 2027; Phase 2 FTD study to initiate in 2H 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.